-
Technology/Science
[JW R&D] Installed ‘No. 1’ Blood Irradiator SANGRAY in Korea
2021-02-11 -
Technology/Science
[JW R&D] JW Leading the Dream of Completely Conquering Atopic Dermatitis
2021-03-09 -
Technology/Science
[JW R&D] JW starts up developing ‘innovative infusion solution plant facility’ jointly with public a
2021-03-09
-
Technology/Science
[JW R&D] JW, ‘Receiving Attention’ as a Leader of Innovative New Drugs (First-in-Class)
2021-03-09 -
Technology/Science
[JW R&D] Renal Anemia Treatment of JW Pharmaceutical, Achieved New Drug Approval in Japan
2021-03-09 -
Technology/Science
[JW R&D]JW, Making a New History of Developing Innovative New Drugs (first-in-class) in Korea
2021-03-09
PR more
- JW Holdings to Begin Exporting Total Parenteral Nutrition 'WINUF' to Mongolia through AsiaPharma LLC.
- Hair Loss Treatment by JW0061-mediated Wnt modulation for “Growth in Hair length & follicular number”
- JW Group Expands Global Territory of 'R&D Open Innovation'
- JW Pharmaceutical’s Licensed Out ‘New Atopic Dermatitis Drug Candidate’ (JW1601) to enter Phase 2b dose-ranging clinical trial
- JW Bioscience signs a non-exclusive license agreement with Immunovia (Sweden) for the patent ‘diagnostic biomarker of pancreatic cancer’
- JW Pharmaceutical Corporation signed a License Agreement for Fostamatinib with Kissei Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company.
JW of the day